STOCK TITAN

Agilent Technologies (A) Stock Price, News & Analysis

A NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
2 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
+16.9% close of May 28, 2026
1-year change
+23.2% closing prices, November 18, 2025 to November 18, 2026
1-month change
+2.5% closing prices, October 16, 2026 to November 18, 2026

Company Description

Agilent Technologies Inc. (NYSE: A) is a global company in the field of analytical and clinical laboratory technologies. The company describes itself as delivering insights and innovation that help customers "bring great science to life." Agilent offers a full range of solutions that include instruments, software, services, and expertise, which are used to provide trusted answers to customers’ most challenging scientific and analytical questions.

According to its public materials, Agilent’s technologies support laboratories and organizations across life sciences, diagnostics, and applied markets. The company is associated with the analytical laboratory instrument manufacturing industry within the broader manufacturing sector. Its measurement and laboratory technologies are used in areas such as biopharmaceutical and chemical applications, advanced materials, clinical laboratories, environmental analysis, forensics, food-related testing, academic research, and government-related organizations, as described in historical overviews of the business.

Agilent states that it operates on a global scale and employs approximately 18,000 people worldwide. The company reports that it generated revenue of $6.95 billion in its fiscal year ended October 31, 2025, and $6.51 billion in fiscal year 2024. These figures underscore the scale of its operations in the laboratory technology and diagnostics markets. Agilent’s common stock is registered under the symbol A on the New York Stock Exchange.

Business focus and solutions

Agilent describes its offering as a full range of laboratory-focused solutions. These include analytical instruments, software for data handling and analysis, and a variety of services and expertise that support customers across the lifecycle of their scientific and analytical workflows. The company emphasizes that its solutions are intended to provide reliable, trusted answers in complex laboratory environments, from research through applied and regulated settings.

In its communications, Agilent highlights its role in life sciences and diagnostics. The company has referenced three operating groups in its financial reporting: the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These groups reflect how Agilent organizes its activities across different laboratory markets and service models, including instruments, consumables, and service-oriented offerings.

Life Sciences and Diagnostics Markets Group

The Life Sciences and Diagnostics Markets Group (LDG) focuses on markets related to life sciences research and diagnostic applications. In its financial disclosures, Agilent reports revenue and operating margin for this group, indicating that it is a distinct operating segment. LDG’s activities relate to technologies and solutions used in life science laboratories and diagnostic settings, where accurate measurement and analysis are critical.

Agilent CrossLab Group

The Agilent CrossLab Group (ACG) is reported as another operating segment. Agilent associates this group with revenue from activities that extend beyond instruments alone, including services and other offerings that support laboratory operations. In its segment reporting, the company presents ACG revenue and operating margins separately, indicating that this group plays a specific role in its overall business model and customer engagement.

Applied Markets Group

The Applied Markets Group (AMG) is the third operating group highlighted in Agilent’s financial reports. This group addresses applied markets, which can include areas such as chemical analysis, advanced materials, and other non-clinical applications where analytical laboratory technologies are required. Agilent reports AMG’s revenue and operating margin, underscoring its contribution to the company’s diversified participation in analytical and applied science markets.

Agilent also develops software and systems that address regulatory requirements in laboratory and manufacturing environments. For example, the company has announced 21 CFR Part 11 compliance software for the Agilent xCELLigence Real-Time Cell Analysis (RTCA) eSight system. This software includes a compliance license and enhanced security features, with capabilities such as secure user authentication, electronic signatures, and complete audit trails. Agilent states that these features are intended to support deployment of the RTCA eSight system in GMP-regulated manufacturing and quality control settings, in addition to its use in drug discovery and development laboratories.

By adding Part 11 compliance and security features to the xCELLigence RTCA eSight platform, Agilent indicates that it aims to support continuity from early-stage drug discovery and research through to production. The company describes this as helping users ensure that electronic records and audit trails are trustworthy, attributable, and compliant with regulatory expectations in biopharma and cell therapy manufacturing environments.

Chromatography and biotherapeutics applications

Agilent has also announced products in the area of liquid chromatography for biotherapeutics. The company introduced Agilent Altura Ultra Inert HPLC Columns, which it describes as high performance liquid chromatography columns suited for biotherapeutics applications. According to Agilent, these columns are designed for demanding applications including peptide GLP-1 and oligonucleotide therapeutic development and quality control.

In its description of the Altura Ultra Inert HPLC Columns, Agilent highlights attributes such as faster conditioning, improved peak shape, and enhanced sensitivity. The company associates these columns with its proprietary Ultra Inert technology and positions them as part of a broader inert sample flow path portfolio. Agilent presents this launch as reinforcing its focus on products that support the development and production of high-quality therapeutics in the biopharmaceutical sector.

Financial reporting and segment information

Agilent’s SEC filings and press releases provide insight into its financial structure and reporting practices. The company reports consolidated financial results, including net revenue, costs and expenses, income from operations, and net income. It also discloses segment-level revenue and operating margins for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group.

Agilent uses both GAAP and non-GAAP financial measures in its communications. In its Form 8-K filings regarding quarterly results, the company explains that it provides non-GAAP financial information to offer supplemental insight into operational performance. It notes that these non-GAAP measures exclude items such as restructuring and amortization, and that management uses them for internal comparisons and to evaluate performance relative to historical results and other companies. Agilent also states that non-GAAP information is not an alternative to GAAP and may differ from similar measures used by other companies.

Capital markets and shareholder returns

Agilent’s common stock is registered on the New York Stock Exchange under the symbol A. The company has announced cash dividends on its common stock, stating, for example, a quarterly dividend amount and record and payment dates in its public news releases. Agilent notes that the timing and amounts of future dividends are subject to determination and approval by its board of directors, indicating a board-governed approach to capital return decisions.

In addition to dividends, Agilent’s financial statements and cash flow information show activities such as repurchases of common stock, issuance and repayment of long-term debt, and investments in property, plant, and equipment. These disclosures illustrate how the company allocates capital among operations, shareholder returns, and investment in its asset base.

Corporate governance and leadership changes

Agilent reports changes in its senior leadership through Form 8-K filings. For example, the company has disclosed the resignation of a chief financial officer, the appointment of an interim CFO, and later the appointment of a new senior vice president and chief financial officer and principal financial officer. These filings include information about the appointees’ prior roles, compensation arrangements, and equity awards, as well as references to change-of-control agreements and stock plans. Through these disclosures, Agilent provides transparency into its governance processes and executive compensation structures.

Use of Agilent technologies

Across its public communications, Agilent emphasizes that its instruments, software, services, and expertise are used to address complex analytical challenges in laboratories worldwide. The company positions its technologies as tools that enable customers to generate reliable data, support regulatory compliance where required, and advance scientific discovery and product development in fields such as life sciences, diagnostics, and biopharmaceutical manufacturing.

Stock Performance

$177.26
+2.93%
+5.04
Last updated: at
+23.2%
Performance 1 year
$50.0B

Agilent Technologies (A) closed at $177.26 on November 18, 2026. Over the past 12 months, the price has gained 23.2%.

See what a $1,000 investment in A would be worth today

Average down calculator for A

A Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
634
Shares Sold
1
Transactions
Most Recent Transaction
Dolsten Mikael (Director) sold 634 shares @ $151.38 on September 4, 2026

Insider selling at Agilent Technologies over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Agilent Technologies generated $6.9B in revenue in FY2025, retaining a 52.4% gross margin, operating income reached $1.5B (21.3% operating margin), and net income was $1.3B, reflecting a 18.8% net profit margin. Diluted earnings per share stood at $4.57. The company generated $1.6B in operating cash flow. The current ratio was 1.96, measuring current assets divided by current liabilities.

$6.9B
Revenue (FY2025)
$1.3B
Net Income (FY2025)
$1.6B
Operating Cash Flow

Upcoming Events

NOV
23
November 23, 2026 Earnings

Q4 2026 Results

Earnings release after market close on 2026-11-23. Results to be posted on Agilent Investor Relations website (Events section).
NOV
23
November 23, 2026 Earnings

Earnings Conference Call

Listen-only conference call at 1:30 p.m. PST on 2026-11-23; webcast via Agilent Investor Relations Events; recording available 90 days.
DEC
01
December 1, 2026 - December 1, 2026 Marketing

Evercore fireside chat

Management fireside chat at Evercore Healthcare Conference in Coral Gables, FL. Live audio webcast and replay on Agilent IR.
JAN
05
January 5, 2027 Financial

Record date

Shareholders of record at close Jan 5, 2027 will be entitled to the $0.2625 per share quarterly cash dividend payable Jan 27, 2027.
JAN
27
January 27, 2027 Financial

Dividend payment

Agilent to pay quarterly cash dividend of $0.2625 per share on Jan 27, 2027 to shareholders of record as of Jan 5, 2027.

Agilent Technologies has 5 upcoming scheduled events. The next event, "Q4 2026 Results", is scheduled for November 23, 2026 (in 5 days). 2 of them are earnings releases or calls. 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the A stock price.

Short Interest History

Last 12 Months

Short interest in Agilent Technologies (A) currently stands at 4.9 million shares, down 2.6% from the previous reporting period, representing 1.7% of the float. Since November 2025, short interest has increased by 49.6%.

Days to Cover History

Last 12 Months

Days to cover for Agilent Technologies (A) currently stands at 2.2 days, down 7.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 68.4%. Across the settlements charted above, it has ranged from 1.3 to 3.8 days.

A Company Profile & Sector Positioning

Agilent Technologies (A) operates in the Diagnostics & Research industry within the broader Healthcare sector and is listed on the NYSE. Among dividend-paying stocks, A ranks #1,893 by dividend yield.

Investors comparing A often look at related companies in the same sector, including Waters Corp (WAT), Idexx Laboratories Inc (IDXX), IQVIA Holdings Inc. (IQV), Natera, Inc. (NTRA), and Mettler-Toledo International (MTD). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate A's relative position within its industry.

Frequently Asked Questions

The current stock price of Agilent Technologies (A) is $177.26 as of November 18, 2026.

The market cap of Agilent Technologies (A) is approximately $50.0B. Learn more about what market capitalization means .

The FY2025 revenue of Agilent Technologies (A) is $6.9B, from its most recent completed fiscal year.

The FY2025 net income of Agilent Technologies (A) is $1.3B, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Agilent Technologies (A) is $4.57 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Agilent Technologies (A) is $1.6B for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Agilent Technologies (A) is 18.8% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Agilent Technologies (A) is 21.3% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Agilent Technologies (A) is 52.4% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Agilent Technologies (A), current assets divided by current liabilities, was 1.96 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Agilent Technologies (A) is $3.6B for FY2025, its most recent completed fiscal year.

The operating income of Agilent Technologies (A) is $1.5B for FY2025, its most recent completed fiscal year. Learn about operating income.

Agilent Technologies Inc. is a global company in analytical and clinical laboratory technologies. It offers a full range of solutions that include instruments, software, services, and expertise, which are used to provide trusted answers to customers’ most challenging scientific and analytical questions in life sciences, diagnostics, and applied markets.

Agilent operates in the analytical laboratory instrument manufacturing industry within the broader manufacturing sector. Its technologies support analytical and clinical laboratory applications across life sciences, diagnostics, and various applied markets.

Agilent’s common stock is registered on the New York Stock Exchange under the ticker symbol A. This listing information is disclosed in the company’s SEC filings.

Agilent states that it provides a full range of solutions for laboratories, including analytical instruments, software, services, and scientific expertise. These offerings are intended to help customers generate reliable data and address complex analytical and clinical questions.

Agilent reports three operating groups in its financial disclosures: the Life Sciences and Diagnostics Markets Group (LDG), the Agilent CrossLab Group (ACG), and the Applied Markets Group (AMG). Each group focuses on different laboratory markets and revenue streams within the company’s overall business.

Agilent describes itself as a global leader in analytical and clinical laboratory technologies, with a focus on delivering insights and innovation that help customers bring great science to life. Its Life Sciences and Diagnostics Markets Group reflects this emphasis on life science research and diagnostic applications.

Agilent has announced 21 CFR Part 11 compliance software for its xCELLigence Real-Time Cell Analysis (RTCA) eSight system. The company states that this software includes a compliance license and enhanced security features such as secure user authentication, electronic signatures, and complete audit trails, supporting use of the system in GMP-regulated manufacturing and quality control settings.

Agilent has introduced Altura Ultra Inert HPLC Columns as high performance liquid chromatography columns suited for biotherapeutics applications. The company notes that these columns are designed for demanding uses, including peptide GLP-1 and oligonucleotide therapeutic development and quality control.

Yes. In its Form 8-K filings and earnings press releases, Agilent explains that it provides non-GAAP financial information, such as adjusted net income and earnings per share. The company states that these measures are intended to offer meaningful supplemental information about operational performance and to facilitate comparisons with historical results and other companies.

Agilent reports that it generated revenue of $6.95 billion in its fiscal year ended October 31, 2025, and $6.51 billion in fiscal year 2024. The company also states that it employs approximately 18,000 people worldwide, indicating a large global presence in analytical and clinical laboratory technologies.

Agilent has announced cash dividends on its common stock in public news releases, specifying per-share amounts and relevant record and payment dates. The company notes that the timing and amounts of future dividends are subject to determination and approval by its board of directors.

Based on the company’s descriptions, Agilent’s technologies are used by organizations involved in life sciences, diagnostics, and applied markets, including biopharmaceutical and chemical applications, advanced materials, clinical laboratories, environmental and forensic analysis, food-related testing, academic research, and government-related organizations.